Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00769886 · ClinicalTrials.gov registry record · Phase 3
Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.
A Phase 3 study, sponsored by Bausch & Lomb Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 144
- Enrollment target
NCT00769886 is a Phase 3 study that has completed, run by Bausch & Lomb Incorporated. The registered enrollment target is 144 participants.
The verdict
NCT00769886, a Phase 3 study, has completed, sponsored by Bausch & Lomb Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 144 participants
- Enrollment target
Study Summary
The purpose of this study is to establish the safety and efficacy of ketotifen/naphazoline ophthalmic solution compared to vehicle and its individual components in alleviating the signs and symptoms of conjunctival allergen challenge (CAC)-induced allergic conjunctivitis.
Interventions
- DRUG Vehicle
- DRUG Ketotifen
- DRUG Ketotifen/naphazoline
- DRUG Naphazoline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2008-10 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00769886
The ClinicalTrials.gov registry entry for NCT00769886 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Vehicle is the first listed.
NCT00769886 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00769886 about?
NCT00769886 is a clinical study titled "Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.". The purpose of this study is to establish the safety and efficacy of ketotifen/naphazoline ophthalmic solution compared to vehicle and its individual components in alleviating the signs and symptoms of conjunctival allergen challenge (CAC)-induced allergic conjunctivitis.
What is the current status of trial NCT00769886?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 144 participants. The study started on 2008-10. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00769886?
The interventions under investigation include: Vehicle (DRUG), Ketotifen (DRUG), Ketotifen/naphazoline (DRUG), Naphazoline (DRUG).
Who is sponsoring clinical trial NCT00769886?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.